Methylone
Thirty years from a Shulgin patent to a Phase 3 PTSD asset — by way of a smoke-shop shelf.
Methylone (3,4-methylenedioxy-N-methylcathinone; βk-MDMA) is the β-ketone analogue of MDMA. It was patented in 1996 as a candidate antidepressant and antiparkinsonian, surfaced as a grey-market designer drug in the Netherlands in 2004, became a defining constituent of the American “bath salts” market, was placed in Schedule I in 2011–13, and — as TSND-201 — now holds FDA Breakthrough Therapy designation with a positive Phase 2 trial in JAMA Psychiatry. This report separates what the literature establishes from what remains inference.
It was a medicine before it was a street drug.
Jacob and Shulgin filed WO 96/39133 in June 1996, assigned to Neurobiological Technologies, explicitly claiming antidepressant and antiparkinsonian utility. Recreational appearance came eight years later.
Mechanism: transporter-level, not receptor-level.
It is a substrate and reuptake inhibitor at DAT, NET and SERT with no direct 5-HT2A agonism, and roughly ten-fold weaker VMAT2 activity than MDMA — the likely reason it does not deplete brain serotonin.
The abuse-era evidence is real but confounded.
Almost all toxicology comes from binge-dosing models or polydrug fatalities in which methylone was one analyte among several. Species and regimen drive the neurotoxicity findings.
Phase 2 hit, at a modest effect size.
IMPACT-1 (n = 65) showed a placebo-adjusted CAPS-5 improvement of 9.64 points at Day 64 (p = 0.011), significant from Day 10, with no hallucinations and no AE-driven discontinuations.
The commercial thesis is operational, not just biological.
Shorter sessions, no manualised trauma-processing psychotherapy, and apparent SSRI compatibility are the differentiators from the MDMA-assisted model that FDA rejected in 2024.
Most of the therapeutic literature has one sponsor.
The preclinical neuroplasticity work, the case series and the trial share authors with equity in the developer. That does not invalidate it; it does mean independent replication is the load-bearing gap.
Thirty years in eleven moments
Origins:
a designed antidepressant
Methylone belongs to a chemical lineage that is older than the designer-drug era it is usually filed under. Cathinone itself is the principal stimulant of Catha edulis (khat), chewed in East Africa and the Arabian Peninsula since at least the tenth century; its synthetic N-methyl homologue, methcathinone, was described in 1928–29 and was marketed as an antidepressant in the Soviet Union in the 1930s under the name ephedrone before being prohibited there in the 1990s after decades of misuse.7 The pattern — therapeutic intent, then diversion — is the family's default, not methylone's exception.
Methylone was prepared independently by two groups in the mid-1990s: Dal Cason, Young and Glennon's survey of N-alkyl and methylenedioxy-substituted cathinone analogues,8 and Peyton Jacob III and Alexander Shulgin.1 Jacob and Shulgin filed on 6 June 1996 — WIPO application WO 96/39133, Novel N-Substituted 2-Amino-3′,4′-Methylene-Dioxypropiophenones, assigned to Neurobiological Technologies Inc. of Emeryville, California. The patent positioned the series as candidates for antidepressant and antiparkinsonian use, on the reasoning that a compound acting on dopaminergic and serotonergic pathways might serve both.1,2 No clinical programme followed. The compound sat unexploited for a decade.
“Almost the same potency of MDMA, but it does not produce the same effects… an almost antidepressant action, pleasant and positive, but not the unique magic of MDMA.”
Shulgin's own assessment is worth holding onto, because it anticipates the modern development thesis almost exactly: equipotent with MDMA, mood-elevating, but without the immersive, distinctively empathogenic quality. What reads in 1996 as a disappointment reads in 2026 as a product profile — a drug that moves affect without producing a six-to-nine-hour altered state requiring two therapists in the room.
Structurally the difference from MDMA is a single atom-group: a ketone at the benzylic position. MDMA is, formally, the deketo form of methylone.4 That β-keto group is what defines the whole synthetic-cathinone class, and — as Section IV sets out — it is not pharmacologically silent.
Explosion, bath salts, and the Molly supply
Methylone's recreational career began with a product that was not sold as a drug at all. In late 2004 a liquid called “Explosion” appeared in Dutch smartshops and online: 5 mL plastic tubes labelled “Room odorizer Vanilla. Do not ingest. Keep away from children. Never use more than one bottle.” Analysis identified the active constituents as methylone and mCPP.5,6 The labelling was the point: a “not for human consumption” wrapper around an uncontrolled psychoactive was the template the entire novel-psychoactive-substance market would use for the next decade.
Synthetic cathinones circulated in Europe from roughly 2003 and did not reach the US illicit market until 2010 — after which uptake was near-vertical. American poison-control centres recorded 0 synthetic-cathinone exposures in 2009, 304 in 2010, and 6,156 in 2011.6 Products were retailed in convenience stores, head shops and by mail order, in 200 mg and 500 mg foil packets branded Ivory Wave, Purple Wave, Vanilla Sky, Bliss, Cloud Nine, Meow Meow, and dozens more, nominally as bath salts, plant food or fertiliser.9,10
Two distinct consumer channels ran in parallel, and conflating them is a common analytical error. The bath-salts channel was insufflated or injected stimulant use, frequently polydrug, and generated the psychiatric emergencies — agitation, paranoia, psychosis — that drove the moral panic. The second channel was substitution: methylone was widely sold as MDMA in “Molly” capsules,11 meaning a large share of exposures were to users who believed they had taken MDMA, at MDMA doses, in MDMA settings (hot, crowded, dehydrating) — a context that matters enormously for thermoregulatory risk.
Supply was industrial and international. In a representative 2012 federal prosecution, a nineteen-year-old in Fairfax, Virginia pleaded guilty to leading a ring that ordered multi-kilogram quantities of methylone from a Chinese source, shipped to a post-office box from summer 2011 through May 2012 for distribution across northern Virginia; he was the last of eight defendants to plead.10 US Customs and Border Protection encountered 352 shipments of synthetic-cathinone products between June 2008 and December 2012; methylone was the single most commonly identified compound, present in 145 of them.12
The cultural framing that resulted — cannibal-headline “bath salts,” a Schedule I stimulant with no medical value — is the inheritance the current clinical programme has to work against. It is also, in a narrow sense, an inheritance of the labelling, not of the pharmacology.
Federal forensic exhibits identifying methylone, 2009–2012
A 130-fold rise across four years. 404 exhibits were logged in total over the period; the scheduling record leans heavily on this curve.
The scheduling record
The United Kingdom moved first and most inventively. Acting on Advisory Council on the Misuse of Drugs advice, the Misuse of Drugs Act 1971 (Amendment) Order 2010 brought mephedrone and cathinone derivatives generally under Class B control from 16 April 2010 — by generic definition rather than by name, which the Home Office minister described to Parliament as “a world first for this group of drugs.”13 Methylone was named in debate as one of the derivatives already seen in the UK and likely to be “the next problematic substance” had the order been drawn narrowly.14 The ACMD's supporting report cited at least 25 UK deaths in which cathinones were implicated and noted drily that none of the compounds has any efficacy as plant fertiliser and none would function as bath salts.15 Germany had already controlled methylone under the Betäubungsmittelgesetz in January 2009; Japan scheduled it in the same period.15,16
The US sequence was slower and used the temporary-scheduling machinery. DEA published a Notice of Intent on 8 September 2011 and a final order on 21 October 2011 placing methylone, mephedrone and MDPV in Schedule I on an emergency basis, effective for at least a year while DEA and HHS studied permanent control — the stated justification being “an imminent threat to the public safety.”17 Congress then permanently scheduled mephedrone and MDPV through the Synthetic Drug Abuse Prevention Act of 2012, which also wrote a prospective ban on future bath-salt analogues.18,19 Methylone was the substance left out of the statute; DEA finished the job administratively, and its final rule of 12 April 2013 placed methylone permanently in Schedule I. Notably, no interested party requested a hearing, so the Administrator issued the order without one.12
Schedule I placement rests on three statutory findings, one of which is no currently accepted medical use. A successful Phase 3 programme would put that 2013 finding in direct tension with an NDA. The practical resolution is rescheduling on approval — the path esketamine and, in principle, MDMA were on. This is a live regulatory question for the asset, not a settled one, and it is under-discussed in the trial literature.
A parallel legal thread deserves flagging for completeness: because methylone was structurally a near-neighbour of an already-scheduled drug, US prosecutors in the 2010–11 window also had recourse to the Controlled Substance Analogue Enforcement Act. Analogue prosecutions were contested on vagueness grounds throughout this period, and the emergency-scheduling route was in part a way around that fight.
Mechanism of action
Methylone acts at the plasma-membrane monoamine transporters, functioning both as a reuptake inhibitor and — because it is itself transported — as a substrate that triggers non-exocytotic, transporter-mediated efflux of cytoplasmic monoamine.20,21 This is the amphetamine mechanism, not the psychedelic one. There is no significant direct receptor agonism driving the effect.
The primary evidence
The anchor study is Baumann and colleagues at the NIDA intramural programme (2012) — a paper on which Shulgin himself is a co-author. In rat brain synaptosomes, methylone was a non-selective substrate for DAT, NET and SERT, comparable to MDMA in both potency and selectivity. In vivo microdialysis in rat nucleus accumbens showed dose-related increases in extracellular dopamine and 5-HT after 0.3 and 1.0 mg/kg i.v., with the 5-HT effect larger than the dopamine effect. Both methylone and mephedrone were weak motor stimulants relative to methamphetamine.20
The same paper delivered the finding that has become the therapeutic argument. Repeated dosing (3.0 and 10.0 mg/kg s.c. ×3) produced hyperthermia but no long-term change in cortical or striatal amines, whereas an equivalent MDMA regimen (2.5 and 7.5 mg/kg ×3) produced robust hyperthermia and persistent depletion of cortical and striatal serotonin.20 Methylone raises serotonin without emptying the tank.
A heterologous-expression study in CHO cells found a different rank order — NET > DAT > SERT for uptake inhibition, with no activity at GABA transporter 1 — and reported that methylone alone was non-cytotoxic except at high concentrations, but synergistically cytotoxic in combination with methamphetamine in transporter-expressing cells.16 The discrepancy with Baumann's “non-selective, MDMA-like” profile is a genuine one and is assay-dependent: synaptosomal release assays and heterologous uptake-inhibition assays do not measure the same thing. Any single potency table for this compound should be read with that caveat.
What it does not do
Three negative findings do most of the differentiating work:
- No 5-HT2A activity. No direct agonist or antagonist activity at 5-HT2A has been detected — consistent with an absence of head-twitch response in rodents and of hallucinations in human dosing.22 This is what licenses the “non-hallucinogenic neuroplastogen” framing.
- >10-fold weaker VMAT2 activity than MDMA. MDMA disrupts vesicular serotonin stores via VMAT2; methylone largely does not, which is the mechanistic candidate for the non-depletion result above.22,23
- Broad receptor silence. The sponsor reports no agonist or antagonist activity across a 168-GPCR panel, and weak-to-absent affinity for other 5-HT, NE and DA receptors.22,24 A possible 5-HT1A partial agonism has been proposed to explain anxiolysis, but is not supported by all reports and should be treated as unresolved.23
The neuroplasticity mechanism (2025–26)
The most recent and most consequential mechanistic work is Warner-Schmidt et al. in Neuropsychopharmacology. In cultured cortical neurons, methylone stimulated neurite outgrowth — increasing both branch number and longest-neurite length. Critically, the two effects dissociate pharmacologically: branching was blocked by monoamine-transporter inhibitors (reboxetine, escitalopram, JHW-007), while longest-neurite growth was blocked by trkB and mTOR inhibition (Ana-12, rapamycin). RNA-seq with functional enrichment indicated long-lasting transcriptional effects on outgrowth mediators, and behaviourally methylone produced rapid and durable improvements in fear-extinction learning and recall. Reboxetine abolished the extinction-recall benefit, implying NET activity is required for the behavioural effect.24
This is the cleanest mechanistic story on offer: transporter engagement → BDNF/trkB–mTOR signalling → structural plasticity → enhanced fear extinction — with no 5-HT2A step. It converges downstream with where ketamine and psilocybin are thought to act while arriving by a different route. Independent groups have reported compatible findings on fear memory and amygdala activity25 and on antidepressant-relevant and prosocial effects,26 which materially strengthens the case; the neurite/RNA-seq work itself remains single-lab.
Target engagement: methylone vs MDMA
Relative activity, MDMA normalised to full scale at each target. Bars encode direction and approximate magnitude of the reported differences, not interchangeable numeric potencies.
Repeated methylone dosing does not persistently deplete cortical or striatal 5-HT; matched MDMA dosing does.20
Fluoxetine pre-treatment did not blunt methylone's FST effect; SSRIs measurably dampen MDMA's clinical effect.22
Faster onset, shorter duration, non-hallucinogenic — dosing visits roughly half the length of MDMA's 6–9 h.27
Caveat on this figure. Reported potencies vary substantially by preparation — rat synaptosomal release assays yield an MDMA-like non-selective profile,20 while CHO-cell uptake inhibition yields NET > DAT > SERT.16 The bars above are our qualitative synthesis of the direction of the differences, not a harmonised potency table. No such harmonised table exists in the literature.
Abuse liability, toxicology, and the neurotoxicity dispute
Methylone is reinforcing. Rodent self-administration work established rewarding and reinforcing properties consistent with its dopaminergic action,28 and Baumann's group explicitly flagged that the dopaminergic component “may contribute to their addictive potential” while noting the hypothesis awaited confirmation.20 Nothing in the therapeutic programme resolves this; it is why a Schedule I-derived asset will carry an abuse-liability and diversion package into any NDA.
The neurotoxicity literature does not agree with itself
This is the most important epistemic point in the report, and it cuts both ways.
rat
mouse & rat
mouse, binge
transporter KO mice
The reasonable reading: methylone's neurotoxic signal is regimen- and species-dependent, and moderate relative to MDMA and methamphetamine. A review of β-ketoamphetamine neurotoxicology concludes that synthetic cathinones are “not consistently associated” with long-term DA or 5-HT depletion and that their effects on these parameters appear more moderate than the non-keto amphetamines.31 What is not established is that repeated therapeutic-range human dosing is neurotoxically benign; no human neuroimaging or biomarker study addresses this.
Human fatalities and cardiovascular risk
Mortality attribution is genuinely messy. A review counts at least four US deaths and one in France attributed to methylone toxicity.4 Against that, the Miami-Dade Medical Examiner reported 72 cases from 2011 in which methylone was identified on routine toxicology — of which 46 were classified homicides, 8 suicides, 16 accidents and 2 undetermined.11 Those 72 are decedents in whom the drug was present, not deaths it caused; the distinction is routinely lost in secondary coverage and it inflates the apparent lethality.
Cardiovascular toxicity remains an open and actively-studied liability. Recent work implicates oxidative stress in methylone cardiotoxicity32 and characterises cardiovascular effects of realistic bath-salt mixtures (methylone with MDPV and caffeine) in rats.33 Blood-pressure increase appears among the treatment-emergent adverse events in IMPACT-1.34
Two structural confounds run through the whole abuse-era toxicology. First, polydrug exposure: methylone was frequently co-ingested with MDPV, and one in vitro study found frank synergy with methamphetamine on transporter-expressing cells.16 Second, setting: much of the exposure was as counterfeit MDMA in hot, crowded environments, where thermoregulatory failure is a known amplifier of amphetamine-type toxicity independent of the specific molecule.
The β-keto family: each cathinone is an amphetamine with a ketone
Every entry below is the β-keto homologue of a familiar amphetamine-type compound. The naming convention (“bk-”) makes the mapping explicit and explains why generic legislative definitions, rather than compound-by-compound listing, became the regulatory tool of choice.
= MDMA + ketone
Sources: 4, 7, 13, 15. Methcathinone (ephedrone, 1928) is the family's progenitor and, tellingly, its first therapeutic — a 1930s Soviet antidepressant withdrawn for abuse.
Prior development attempts and the IP position
On the direct question — what else was methylone ever developed for — the honest answer is nothing that reached the clinic before 2021. The 1996 filing named two indications, depression and Parkinson's disease, and neither was pursued. Neurobiological Technologies, the assignee, developed no methylone product. We found no evidence of veterinary development, no evidence of an anorectic or smoking-cessation programme (a plausible-sounding path, given that bupropion is a structurally-related β-keto compound and was explicitly carved out of the UK generic cathinone definition35), and no IND or clinical registration for methylone anywhere before the Transcend programme.
This is worth stating plainly because “originally developed as X” claims about methylone circulate widely and mostly trace back to a single patent's stated utility, not to a development effort. The compound's pre-2021 history is a patent, a handful of pharmacology papers, and a large illicit market.
6 Jun 1996
15 Aug 2022
The strategic implication is that regulatory exclusivity — new chemical entity status is unavailable, but orphan-style and data exclusivity, plus the Breakthrough and now National Priority Voucher pathways — matters more here than patent life. Otsuka's acquisition of Transcend, announced 27 March 2026 and completed 12 June 2026, should be read in that frame.36
TSND-201: the current programme
The evidentiary chain
The programme did not begin with a hypothesis; it began with clinical observation. Four early human studies described methylone as well tolerated with a milder effect profile than MDMA — including a controlled head-to-head comparison of acute pharmacological effects in humans and a matched pharmacokinetic study.37,38 A retrospective case series reported symptomatic benefit in PTSD patients with long-term follow-up,39 and a second series reported rapid improvement in major depressive disorder.22 Two Phase 1 studies in healthy volunteers established tolerability at 100–150 mg with, as the sponsor's own authors put it, an “effective but gentler” subjective experience than MDMA.22
Preclinical validation followed the clinical signal rather than preceding it. In rats, a single dose of methylone reduced forced-swim immobility from a vehicle baseline of 63.9 ± 2.7% to 31.9 ± 4.7% at 5 mg/kg and 4.2 ± 1.3% at 10–15 mg/kg — a roughly 95% reduction, larger than published figures for sertraline, paroxetine, fluoxetine, desipramine, ketamine, MDMA or psilocybin in the same paradigm — and the effect persisted at least 72 hours after one dose, where three doses of fluoxetine were undetectable by 24 hours. A trend toward less effect at 20–30 mg/kg suggested a possible U-shaped curve.22
Three methodological details keep this honest. Effective FST doses (5–10 mg/kg) produced no locomotor change in the open field, and at 24 h the antidepressant effect persisted while stimulant locomotion had resolved — which addresses, though does not eliminate, the FST's well-known stimulant false-positive problem. Allometric scaling puts the 10–15 mg/kg rat dose at roughly 100–150 mg in humans, the range already tested in Phase 1. And the result directly contradicts the only prior methylone FST study, a mouse binge protocol (25 mg/kg, 3–4 doses over two days) that increased immobility three days later; the authors attribute the divergence to dose and regimen, which is plausible but is a post-hoc reconciliation.22
IMPACT-1
IMPACT-1 (NCT05741710) Part B was a Phase 2 randomised, double-blind, placebo-controlled trial in 65 adults with severe PTSD (CAPS-5 total severity ≥ 35; mean age 43.7; 60.0% female) across 16 sites in the United States, United Kingdom and Ireland. Participants received four once-weekly oral doses and were followed for six weeks after the final dose, to Day 64.34,40
The primary endpoint was met: an LS-mean placebo-adjusted CAPS-5 improvement of 9.64 points at Day 64 (90% CI −16.48 to −2.80; p = 0.011), with significance already established at Day 10 (−8.00 placebo-adjusted; p = 0.012) and maintained throughout.34,41 Secondary endpoints including depressive symptoms and functional impairment also improved.27 Treatment-emergent adverse events were headache, decreased appetite, nausea, dizziness, blood-pressure increase, dry mouth and insomnia — typically confined to the dosing day and resolving within a day. There were no hallucinations and no discontinuations for adverse events.34,42
Participants did not undergo intensive trauma-processing psychotherapy — only non-directive monitoring and facilitative supervision.
That design decision is the whole commercial thesis. FDA's 2024 rejection of MDMA-assisted psychotherapy turned not on whether patients improved but on trial design, data validity and analysis — problems substantially created by the inseparability of drug and elaborate psychotherapy.27 By stripping the psychotherapy, IMPACT-1 tests a drug effect, which is what a drug approval requires. The cost is that the trial cannot tell us whether adding structured integration would do better, and it leaves open whether the observed benefit is durable beyond six weeks post-dose.
Regulatory and corporate trajectory
FDA granted Breakthrough Therapy designation on 10 July 2025 on the strength of the IMPACT-1 result.41 The trial was published in JAMA Psychiatry on 18 February 2026 (83(5):469–477).34,40 Earlier in 2026 the programme received an FDA Commissioner's National Priority Voucher, and — following a presidential executive order that prioritised psychedelic-adjacent compounds holding Breakthrough designation and voucher eligibility — methylone became, somewhat improbably, the compound of note in federal mental-health discussion, ahead of psilocybin, LSD, ibogaine and MDMA.27,36 Otsuka Pharmaceutical announced its acquisition of Transcend on 27 March 2026 and closed on 12 June 2026; Transcend, founded 2021 on approximately $50 M raised, is now a wholly-owned Otsuka America subsidiary, and a Phase 3 PTSD trial is ongoing.36,43
The therapeutic literature on methylone is substantially sponsor-authored. Warner-Schmidt, Stogniew, Mandell and Olmstead were Transcend employees with equity; Kelmendi is a co-founder with equity; Pittenger and Ching were paid consultants; Stein reports consulting income from Transcend among ~20 other companies. Stogniew, Warner-Schmidt and Mandell are co-inventors on the Transcend patent application. All of this is properly disclosed in the primary papers.22,40 It is not evidence of misconduct. It is the reason independent replication — of the neurite/RNA-seq mechanism and of the Phase 2 effect size — is the single most informative thing that could happen next.
IMPACT-1: CAPS-5 improvement from baseline (n = 65)
Points reduction in Clinician-Administered PTSD Scale for DSM-5 total severity. Both arms improve; the placebo-adjusted difference is the drug effect.
Read the placebo arm. Placebo improved 13.64 points — a large response typical of PTSD trials with intensive contact. The 9.64-point drug increment is clinically meaningful but not transformative, and the confidence interval is wide (a plausible true effect anywhere from 2.8 to 16.5 points).
Note the interval convention. A 90% rather than 95% confidence interval was pre-specified — standard for Phase 2 dose-finding, and appropriate here, but it means the result would not necessarily clear a conventional 95% threshold. Phase 3 is the test.
The commercial landscape: psychedelics and entactogens in Phase 2–3
Every psychedelic or psychedelic-adjacent compound in active late-stage psychiatric development. Methylone's row is highlighted. The comparison that matters for TSND-201 is not chemical — it is that methylone is the only entry here that is not psychedelic.
4-PO-DMT
same molecule
CYB003 / HLP003
lysergide D-tartrate
βk-MDMA
via luvesilocin
mebufotenin benzoate
mebufotenin
N,N-dimethyltryptamine
CYB004
midomafetamine
single enantiomer
How to read this table. Two structural facts stand out. First, almost nobody owns their molecule — psilocybin, LSD, DMT, 5-MeO-DMT, MDMA, methylone and 4-OH-DiPT are all unpatentable as compositions, so every programme competes on formulation, route, deuteration or prodrug chemistry. Second, the field has converged on shortening the session: intranasal, inhaled, buccal, subcutaneous and deuterated routes all exist to cut monitored clinic hours, the binding constraint on this entire class.
Methylone's position is genuinely differentiated. Every other compound in this table produces an altered state that has to be supervised, and every other sponsor is engineering around that fact. TSND-201 sidesteps it: no 5-HT2A activity, no hallucinations, four ordinary weekly oral doses. The trade is that methylone must instead answer for an abuse history none of the others carry, and unwind a Schedule I placement on approval. It is also the only entry competing directly with the one programme that failed — MDMA, in PTSD, on precisely the drug-plus-psychotherapy design that TSND-201 abandoned.
Established, probable, speculative
Grading is ours, applied on volume and independence of supporting evidence. A = multiple independent sources, consistent. B = solid primary evidence, limited replication. C = single source, sponsor-derived, or contested.
Established · A
- It is a substrate and reuptake inhibitor at DAT, NET and SERT.16,20,21
- It is the β-keto analogue of MDMA and produces MDMA-like subjective effects, less immersive.4,37
- It was patented in 1996 for depression and Parkinson's, never developed then.1,2
- US Schedule I (2011 temporary, 2013 permanent); UK Class B (2010).12,13,17
- It was a principal “bath salts” constituent and a common MDMA substitute.11,12
Probable · B
- It does not persistently deplete brain serotonin at doses where MDMA does.20,31
- It lacks direct 5-HT2A activity and is non-hallucinogenic at tested doses.22,34
- Neurotoxicity is regimen- and species-dependent and moderate relative to MDMA/METH.29,31
- It enhances fear-extinction learning in rodents — now reported by more than one group.24,25
- It reduces PTSD symptoms vs placebo over 64 days in severe PTSD.34
Speculative · C
- The trkB/mTOR-dependent neurite mechanism as the causal route to clinical benefit — single lab.24
- SSRI co-administration is safe and non-interfering in humans. Rodent FST only; serotonergic-toxicity risk unquantified.22,27
- 5-HT1A partial agonism — reports conflict.22,23
- Durability beyond Day 64, and efficacy without any psychotherapeutic scaffolding.27
- That supervised therapeutic dosing carries acceptable abuse and diversion risk. Unaddressed by any published study.
Research gaps, in order of consequence
No non-sponsor group has reproduced either the neurite-outgrowth/RNA-seq mechanism or the Phase 2 effect size. Every other gap is downstream of this one.
Six weeks after the last dose is not a durability claim. The whole “episodic, non-daily” value proposition rests on months-to-years follow-up that does not yet exist.
The SSRI-compatibility advantage over MDMA is inferred from a rat forced-swim test. Given a serotonin releaser plus an SSRI, this needs a dedicated human interaction study before it can be marketed as a feature.
The non-depletion argument is entirely rodent. No human imaging, CSF or biomarker study has examined serotonergic integrity after repeated therapeutic dosing.
Blood-pressure increase was a TEAE in a 65-patient trial. PTSD populations carry elevated cardiometabolic risk; the exposed denominator is far too small to characterise this.
Human abuse-potential studies of the pharmaceutical formulation are not in the public literature, and the rescheduling pathway from Schedule I on approval has not been publicly mapped.
IMPACT-1 shows a drug effect without manualised therapy. It does not show that therapy adds nothing. A three-arm design would answer a question that matters clinically and for reimbursement.
Methylone, MDMA and the βk-family have never been profiled side by side at DAT/NET/SERT/VMAT2 in one lab with one assay. The literature's internal disagreements are largely methodological artefacts nobody has cleaned up.
Sources
Quality tier reflects source type and independence, not agreement with our reading. P1 peer-reviewed primary research or official regulatory instrument · P2 review, secondary compilation, or government report · P3 sponsor communication or trade/expert commentary · P4 community reference, used only for non-load-bearing detail.